won't be able to supply any Begrivac flu virus vaccine doses outside the U.S. during the 2005-06 flu season, but the company said it's working to cover the shortfall with other products.
The Emeryville, Calif., biotech company said there's no change to its already-lowered financial guidance. Chiron made the announcement in a short statement Wednesday, saying the decision was reached after further testing had taken place.
Shares of Chiron were up 1 cent to $35.90.
Last Friday, the company
cut the supply expectations for Begrivac after an examination revealed that some of the doses failed to meet product sterility standards. The company had initially expected to supply about 12 million doses of Begrivac to customers outside the U.S. for the upcoming flu season, but reduced that number to around 4 million before the latest update.
The vaccine is manufactured at Chiron's facility in Marburg, Germany. The company said last week that it wouldn't release any Begrivac until testing was complete. At the same time, it indicated that the results of the additional tests or other developments could prevent any of the vaccine from being supplied.
In June, the company lowered its forecast for production of Fluvirin, another flu vaccine. Chiron expects to make 18 million to 26 million doses of Fluvirin for the 2005-06 flu season, with the vast majority of the supply going to the U.S.